Bad Omen Or Opportunity? Roche’s TIGIT Failure Hits Rivals Hard
Arcus/Gilead Readout Expected Next
After two failures in a row from Roche, the TIGIT hypothesis is looking shaky, but it is too early to write off the class yet.
You may also be interested in...
Failure of the tiragolumab plus Tecentriq combination in first line NSCLC patients is a blow to Roche’s immunotherapy aspirations, and its long-term growth strategy.
AstraZeneca’s PD-L1/CTLA-4 combination could soon be rivalling Roche’s regimen, and may offer greater safety and tolerability for liver cancer patients.
Nektar is hoping the combination of bempegaldesleukin and Opdivo could have better chances in kidney and bladder cancers, but analysts aren’t sure and see other IL-2 therapeutics as having better prospects.